{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:26:14Z","timestamp":1757611574237,"version":"3.44.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"5-6","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.canrad.2025.104676","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T11:58:42Z","timestamp":1752839922000},"page":"104676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypofractionated radiotherapy for pancreatic cancer: What role in 2025?"],"prefix":"10.1016","volume":"29","author":[{"given":"Pauline","family":"Kordalski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2024","series-title":"Panorama des cancers en France","author":"Anon.","key":"10.1016\/j.canrad.2025.104676_bib0200"},{"key":"10.1016\/j.canrad.2025.104676_bib0205","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"Folfirinox or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104676_bib0210","doi-asserted-by":"crossref","first-page":"20210044","DOI":"10.1259\/bjr.20210044","article-title":"The role of radiotherapy in locally advanced pancreatic cancer","volume":"94","author":"Huguet","year":"2021","journal-title":"Br J Radiol"},{"key":"10.1016\/j.canrad.2025.104676_bib0215","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1056\/NEJMra1404198","article-title":"Pancreatic adenocarcinoma","volume":"371","author":"Ryan","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104676_bib0220","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2025.104676_bib0225","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1245\/s10434-009-0409-5","article-title":"AHPBA\/SSO\/SSAT Consensus Conference on resectable and borderline resectable pancreatic cancer: rationale and overview of the conference","volume":"16","author":"Vauthey","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.canrad.2025.104676_bib0230","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1245\/s10434-009-0408-6","article-title":"Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement","volume":"16","author":"Callery","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.canrad.2025.104676_bib0235","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.surg.2014.02.001","article-title":"Borderline resectable pancreatic cancer: a consensus statement by the International Study group of Pancreatic Surgery (ISGPS)","volume":"155","author":"Bockhorn","year":"2014","journal-title":"Surgery"},{"key":"10.1016\/j.canrad.2025.104676_bib0240","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.canrad.2025.104676_bib0245","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.dld.2018.08.008","article-title":"Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, Gercor, Unicancer, SFCD, SFED, SFRO, ACHBT, AFC)","volume":"50","author":"Neuzillet","year":"2018","journal-title":"Digest Liver Dis"},{"key":"10.1016\/j.canrad.2025.104676_bib0250","doi-asserted-by":"crossref","first-page":"413","DOI":"10.5858\/133.3.413","article-title":"The pathology and genetics of metastatic pancreatic cancer","volume":"133","author":"Yachida","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.canrad.2025.104676_bib0255","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0140-6736(69)92326-5","article-title":"Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer","volume":"294","author":"Moertel","year":"1969","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2025.104676_bib0260","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4","article-title":"Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 radsfluorouracil), and high dose radiationfluorouracil: the Gastrointestinal Tumor Study group","volume":"48","author":"Moertel","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2025.104676_bib0265","first-page":"164","article-title":"Multidrug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial","volume":"32","author":"Hazel","year":"1981","journal-title":"J Can Assoc Radiol"},{"key":"10.1016\/j.canrad.2025.104676_bib0270","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/jnci\/80.10.751","article-title":"Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study group","volume":"80","author":"Anon.","year":"1988","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.canrad.2025.104676_bib0275","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","volume":"19","author":"Chauffert","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2025.104676_bib0280","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","article-title":"Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial","volume":"29","author":"Loehrer","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104676_bib0285","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1200\/JCO.2006.07.5663","article-title":"Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in Gercor phase II and III studies","volume":"25","author":"Huguet","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104676_bib0290","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/cncr.22735","article-title":"Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy","volume":"110","author":"Krishnan","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2025.104676_bib0295","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.canrad.2025.104676_bib0300","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1200\/JCO.2022.40.16_suppl.4008","article-title":"Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: first results of the CONKO-007 trial","volume":"40","author":"Fietkau","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.canrad.2025.104676_bib0305","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ijrobp.2015.12.003","article-title":"Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation","volume":"94","author":"Krishnan","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104676_bib0310","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ijrobp.2016.10.030","article-title":"Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials","volume":"97","author":"Petrelli","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104676_bib0315","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/cncr.32756","article-title":"Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): an international systematic review and meta-analysis","volume":"126","author":"Tchelebi","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2025.104676_bib0320","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.radonc.2020.11.006","article-title":"A phase II study of stereotactic radiotherapy after folfirinox for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome","volume":"155","author":"Teriaca","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104676_bib0325","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13014-018-1000-7","article-title":"Optimization of treatment planning workflow and tumor coverage during daily adaptive magnetic resonance image guided radiation therapy (MR-IGRT) of pancreatic cancer","volume":"13","author":"Olberg","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2025.104676_bib0330","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ijrobp.2015.10.015","article-title":"Online magnetic resonance image guided adaptive radiation therapy: first clinical applications","volume":"94","author":"Acharya","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104676_bib0335","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ijrobp.2023.05.023","article-title":"A multi-institutional phase 2 trial of ablative 5-fraction stereotactic magnetic resonance-guided on-table adaptive radiation therapy for borderline resectable and locally advanced pancreatic cancer","volume":"117","author":"Parikh","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104676_bib0340","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","article-title":"Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer","volume":"7","author":"Reyngold","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canrad.2025.104676_bib0345","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/j.ijrobp.2024.07.258","article-title":"Multi-institutional comparison of ablative 5-fraction MR-guided online adapted vs 15\/25-fraction ct-guided offline adapted radiation therapy for locally advanced pancreas cancer","volume":"120","author":"Chuong","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104676_bib0350","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.21873\/anticanres.14133","article-title":"Pathogenesis and treatment of pancreatic cancer related pain","volume":"40","author":"Lohse","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.canrad.2025.104676_bib0355","doi-asserted-by":"crossref","first-page":"e971","DOI":"10.1002\/onco.13796","article-title":"Pancreas cancer-associated pain management","volume":"26","author":"Coveler","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.canrad.2025.104676_bib0360","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/ans.13609","article-title":"Pain in pancreatic cancer: review of medical and surgical remedies","volume":"86","author":"Dobosz","year":"2016","journal-title":"ANZ J Surg"},{"issue":"Suppl 7","key":"10.1016\/j.canrad.2025.104676_bib0365","doi-asserted-by":"crossref","first-page":"vii33","DOI":"10.1093\/annonc\/mds224","article-title":"Pancreatic adenocarcinoma: ESMO\u2013ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Seufferlein","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2025.104676_bib0370","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijrobp.2023.08.055","article-title":"Impact of short-course palliative radiation therapy on pancreatic cancer-related pain: prospective phase 2 nonrandomized Painpanc trial","volume":"118","author":"Tello Valverde","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104676_bib0375","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(24)00223-7","article-title":"Celiac plexus radiosurgery for pain management in advanced cancer: a multicentre, single-arm, phase 2 trial","volume":"25","author":"Lawrence","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104676_bib0380","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1016\/j.prro.2019.07.018","article-title":"Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) guidelines for pancreatic stereotactic body radiation therapy (SBRT)","volume":"10","author":"Oar","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2025.104676_bib0385","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","author":"Herman","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2025.104676_bib0390","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/1533034616650778","article-title":"Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study","volume":"16","author":"Comito","year":"2017","journal-title":"Technol Cancer Res Treat"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825000927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825000927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:40:29Z","timestamp":1756932029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321825000927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":39,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1278321825000927"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104676","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypofractionated radiotherapy for pancreatic cancer: What role in 2025?","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104676","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104676"}}